Enwei Pharmaceutical Co (301331.SZ) Stock Price
Enwei Pharmaceutical Co Price
Revenue has compounded at 6.8% per year over the past 6 years to 898.01 M CNY. Earnings per share have declined at 7.4% per year over the last 6 years. Enwei Pharmaceutical Co's net margin stands at 5.8%, down from 15.0% several years earlier. Enwei Pharmaceutical Co currently offers a dividend yield of about 0.83%. The payout ratio is around 36% of earnings.
Enwei Pharmaceutical Co stock price
Enwei Pharmaceutical Co business model & stock analysis
Frequently asked questions about Enwei Pharmaceutical Co
Converted at the current exchange rate, the Enwei Pharmaceutical Co share trades at 2.89 EUR (21.65 CNY).
The revenue cannot currently be calculated for Enwei Pharmaceutical Co.
The profit cannot currently be calculated for Enwei Pharmaceutical Co.
The P/E ratio cannot be calculated for Enwei Pharmaceutical Co at the moment.
The P/S cannot be calculated for Enwei Pharmaceutical Co currently.
The Eulerpool Quality Score for Enwei Pharmaceutical Co is 2/10.
The ISIN of Enwei Pharmaceutical Co is CNE100005LC7. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Enwei Pharmaceutical Co is 301331.SZ. The ticker symbol is used to trade Enwei Pharmaceutical Co shares on the stock exchange.
Enwei Pharmaceutical Co stock
Enwei Pharmaceutical Co Peer Group
Enwei Pharmaceutical Co FIGI
All fundamentals and in-depth analysis of Enwei Pharmaceutical Co
Our stock analysis for Enwei Pharmaceutical Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Enwei Pharmaceutical Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.